1 / 8

Dr Alan Johnson Clinical Scientist HPA Editor-in-Chief, JAC

Dr Alan Johnson Clinical Scientist HPA Editor-in-Chief, JAC. Journal of Antimicrobial Chemotherapy. Education Income generation. JAC Educational Remit. Disseminate information Basic science Clinical Enhance the evidence base Clinical trials Systematic review Improve patient care.

heinz
Download Presentation

Dr Alan Johnson Clinical Scientist HPA Editor-in-Chief, JAC

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Dr Alan Johnson Clinical Scientist HPA Editor-in-Chief, JAC

  2. Journal of Antimicrobial Chemotherapy • Education • Income generation

  3. JAC Educational Remit • Disseminate information • Basic science • Clinical • Enhance the evidence base • Clinical trials • Systematic review • Improve patient care

  4. Income Generation • Society journal for the British Society for Antimicrobial Chemotherapy • Very active society • Symposia • Workshops • Working parties • Expert advice • Income generation from journal essential for viability of the Society

  5. Income Generation • Subscriptions • Reprints • Supplements • Advertising • JAC needs to be “attractive” to readers, researchers, academia & pharma

  6. Income Generation • Most papers not open access (can be purchased) • Papers free after 1 yr • Only change to open access if business case shows income generation for BSAC would be protected

  7. Issues Relating to Data Sharing • Popular with authors? • Patient confidentiality (case reports etc) • Clinical trials sponsored by pharma • Registries of treatment practice maintained by pharma

  8. Surveillance of AMR • Data supplied by hospitals • Patient confidentiality • Small cell size - deductive disclosure • ONS guidelines: <5 cases • No agreement for sharing of hospital data with third-parties • Interpretation: Shared data misinterpreted

More Related